Prostate cancer is the most common type of cancer in men in the UK and USA. Cancers develop when cells in the body acquire genetic mutations that allow the cells to grow rapidly and form a mass known as a tumor. Prostate cancer cells from different individuals can carry different genetic mutations, which affects whether the disease progresses and how the tumors respond to medical treatments. This genetic variety arises in cancer cells partly from a phenomenon known as genomic instability, in which DNA mutations accumulate due to defects in DNA repair.

Genetic studies of biopsies taken from human prostate cancers have shown that genomic instability causes chromosomes—the structures in which the cell's DNA is organized—to break and then be stuck back together haphazardly. As a result, fragments of chromosomes can end up in the wrong position, be duplicated, or be lost altogether. All of these mutations could spur on the growth of the tumor. However, it is currently not clear why some prostate cancers are more genomically unstable than others, or what exactly causes this instability.

Boysen, Barbieri et al. studied prostate cancer cells taken from patients before they started medical treatment. The experiments show that the cancer cells with high levels of genomic instability also often had mutations in a gene that encodes a protein called SPOP. These mutations occur in about 10 percent of men with prostate cancer and appear early in the development of the tumors. Next, they studied the SPOP protein in zebrafish (which is nearly identical to human SPOP), as well as in mouse and human cells. The experiments show that SPOP normally helps the cell to accurately repair DNA that has been damaged. Mutations in SPOP change the DNA repair process, which lead to genomic instability by increasing the likelihood that broken chromosomes will be stuck back together incorrectly.

Further experiments tested drugs known as PARP inhibitors on mouse and human prostate cancer cells. The drugs, which have been recently tested successfully in patients with prostate cancer, block a different method of DNA repair that operates separately to the one that involves SPOP. When both of these pathways were inactivated—one by the SPOP mutation, the other by the drug—the cancer cells died more quickly. Therefore, men that are diagnosed with types of prostate cancer in which the gene that encodes SPOP is mutated might benefit from treatment with PARP inhibitors or other therapies that affect DNA repair.

Genomic instability is a fundamental feature of human cancer, and DNA repair defects resulting in impaired genome maintenance promote pathogenesis of many human cancers (Hanahan and Weinberg, 2011; Garraway and Lander, 2013). In prostate cancer, structural genomic rearrangements, including translocations (e.g., TMPRSS2-ERG) and copy number aberrations (e.g., 8q gain, 10q23/PTEN loss) are a key mechanism driving tumorigenesis (Visakorpi et al., 1995; Cher et al., 1996; Tomlins et al., 2005; Zhao et al., 2005; Liu et al., 2006; Demichelis et al., 2009; Beroukhim et al., 2010).

Whole genome sequencing (WGS) has allowed an unprecedented insight into the alterations underlying cancer. Recently, WGS of treatment naive, clinically localized prostate cancer revealed a striking abundance of genomic rearrangements, in some samples comparable to the number of rearrangements in metastatic prostate cancer (Baca et al., 2013). Furthermore, the type (intrachromosomal vs interchromosomal) and complexity of rearrangements in these tumors shows remarkable heterogeneity, potentially suggesting distinct mechanisms of instability in different molecular classes of prostate cancer. However, somatic alterations underlying these phenomena remain unexplained.

Mutations in SPOP (Speckle-type POZ protein) occur in around 10% of prostate cancers and represent the most common non-synonymous mutations in primary prostate cancer (Barbieri et al., 2012). SPOP mutations define a distinct molecular class of prostate cancer; they are mutually exclusive with ETS rearrangements but display distinct patterns of somatic copy number alterations (SCNAs) (Barbieri et al., 2012).

Here, we investigated somatic alterations associated with genomic rearrangements in prostate cancer. We show that SPOP mutation is an early event specifically associated with increased intrachromosomal genomic rearrangements. Mechanistically, in vitro and in vivo data suggest that SPOP participates in repair of DNA double strand breaks (DSB), and SPOP mutation impairs homology-directed repair (HDR), instead promoting error-prone non-homologous end joining (NHEJ).

To nominate somatic events associated with structural genomic rearrangements in clinically localized prostate cancer, we examined WGS data from 55 treatment naive prostate cancers (Baca et al., 2013) (Figure 1A). This analysis revealed a bimodal distribution, with a more common, ‘low-rearrangement’ population, and a less frequent ‘high-rearrangement’ population primarily driven by intrachromosomal rearrangements (deletions, inversions, and tandem duplications), rather than balanced interchromosomal rearrangements (Figure 1B). We then analyzed the association between recurrent somatic alterations (point mutations and SCNAs) and number of rearrangements (Figure 1C; Figure 1—figure supplements 1, 2). Several recurrent deletions, primarily on chromosomes 5q and 6q, were significantly associated with intrachromosomal genomic rearrangements (Figure 1—figure supplement 1), and these were completely distinct compared to alterations associated with interchromosomal rearrangements (Figure 1—figure supplement 2). Among recurrent point mutations, only a single lesion—mutation in SPOP—was significantly associated with increased rearrangements (Figure 1C). Consistent with increased intrachromosomal rearrangements, SCNA analysis revealed that SPOP mutant prostate cancers showed significantly higher total copy number alteration burden (Figure 1D).

Figure 1 with 5 supplements see all

Download asset Open asset

SPOP mutation frequently co-occurs with specific SCNAs, designating a molecular class of prostate cancer (Barbieri et al., 2012; Blattner et al., 2014) (Figure 1—figure supplement 3). Independent analysis of SCNAs from three publicly available data sets comprising 430 tumors (Baca et al., 2013; Barbieri et al., 2012; Consortium TCGA, 2015), including 47 SPOP mutant prostate cancers, confirmed that the rearrangement-associated deletions (Figure 1—figure supplement 1) were those enriched in SPOP mutant prostate cancer (Figure 1E). When individually comparing SPOP mutations and associated deletions (CHD1 and MAP3K7), we did not observe significant differences in SCNA burden for any one lesion (Figure 1—figure supplement 4). Analysis of clonality (Baca et al., 2013; Prandi et al., 2014) of specific lesions showed that SPOP mutations were highly clonal compared to loci in the associated deletion peaks, supporting that SPOP mutations precede deletions (Figure 1F). In addition, analysis of dependencies of the lesions supports SPOP mutations preceding CHD1 deletions; no lesions were predicted to precede SPOP mutation (Figure 1—figure supplement 5). Together, these data nominate a distinct prostate cancer class characterized by early SPOP mutations and genomic instability. We posited that the SPOP mutation impacts genome maintenance and prioritized SPOP for functional studies.

We explored the functional role of SPOP in vivo, using zebrafish as a rapidly assessable vertebrate model system. SPOP is highly conserved (97.3% identical at the amino acid level between human and zebrafish, Figure 2—figure supplement 1A). Knockdown of Spop by two different splice-blocking morpholinos (MO5, MO7) dramatically impaired brain and eye development as well as decreased overall body size (Figure 2A,B; Figure 2—figure supplement 1F), resulted in gene expression changes consistent with p53 activation, and apoptosis measured by TUNEL assay (Figure 2C, Figure 2—figure supplement 1E). Microinjection of human SPOP mRNA rescued these phenotypes, confirming specificity of the morpholino effects (Figure 2A–C, Figure 2—figure supplement 1F). To nominate signaling pathways impacted by Spop, we performed transcriptional profiling using RNA-seq on zebrafish with Spop knockdown and ectopic expression of wild-type SPOP (SPOP-wt) and SPOP-F133V, the most commonly mutated residue in prostate cancer (Figure 2D). Consistent with recently reported proteomic data (Theurillat et al., 2014) and heterodimerization between mutant and wild-type SPOP in our models (Figure 2—figure supplement 2), transcriptional responses to SPOP-F133V compared with SPOP-wt and Spop morpholino showed a pattern consistent with dominant negative, selective loss of function; SPOP-F133V correlated with SPOP-wt for some gene sets (Cluster B) and correlated with Spop morpholino for others (Cluster A) (Figure 2D, Figure 2—source data 1). Gene set enrichment analyses (GSEA) revealed gene sets involving DNA repair impacted by modulating SPOP function (Figure 2—source data 2). Notably, the transcriptional response to F133V correlated highly with BRCA1 inactivation (Figure 2E). While SPOP has been previously proposed as involved in DNA damage and repair (DDR) signaling based on in vitro experiments (Zhang et al., 2014a), these results for the first time implicate a functional role for SPOP in DDR signaling in vivo and suggest this function is selectively impaired by prostate cancer-derived SPOP mutations. To test this hypothesis in human prostate cancers, we performed unsupervised hierarchical clustering of transcriptional data from 11 SPOP mutant and 53 SPOP wild-type tumors, based on the transcriptional signature of BRCA1 inactivation (MSigDB: M2748). We observed significant segregation of SPOP mutant tumors (p-value = 9.5e⁻⁰⁷, Figure 2F) using this signature, with less robust segregation of tumors harboring CHD1 or MAP3K7 deletions co-occurring with SPOP mutation (Figure 2—figure supplement 3). These data suggest that human prostate cancers with SPOP mutations show transcriptional effects similar to BRCA1 inactivation, consistent with a role for SPOP in DSB repair. Supporting this hypothesis, we observed a trend of mutual exclusivity between SPOP mutations and BRCA1 alterations in genomic data (p-value = 0.0496, Figure 2—figure supplement 4).

Figure 2 with 4 supplements see all

Download asset Open asset

Figure 2—source data 1

List of genes contained in blocks A, B, and C in the heatmap in Figure 2D.

Provided as excel file.

https://doi.org/10.7554/eLife.09207.010

Download elife-09207-fig2-data1-v2.xls

Figure 2—source data 2

Results from GSEA comparing zebrafish embryos ectopically expressing SPOP-wt or -F133V.

Provided as excel file.

https://doi.org/10.7554/eLife.09207.011

Download elife-09207-fig2-data2-v2.xlsx

Consistent with the hypothesis that SPOP is involved in DSB repair in prostate cells, SPOP forms nuclear foci in prostate cells after γ-irradiation (Figure 3A) and stable expression of SPOP-wt conferred resistance to DSB-inducing agents cisplatin and camptothecin (CPT) (Figure 3—figure supplement 1A,B). To further define the impact of SPOP mutation in response to DNA damage, we utilized primary prostate cells isolated from transgenic mice with Cre-dependent conditional expression of SPOP-F133V. After transduction with Tamoxifen-inducible Cre (Cre-ERT2), cells were treated with 4-OH tamoxifen or vehicle and exposed to ionizing radiation (IR) (Figure 3—figure supplement 2). Spop localized in nuclear foci similar to human LNCaP cells in mouse prostate cells (MPCs) after IR, with no alteration in foci by expression of SPOP-F133V (Figure 3A, Figure 3—figure supplement 1I). Induction of SPOP-F133V resulted in delayed recovery from IR-induced damage as measured by comet assay (Figure 3B). No differences were seen in apoptosis after IR, as measured by PARP cleavage (Figure 3—figure supplement 2), subG1 events, or caspase-3 cleavage (data not shown). To functionally characterize how SPOP mutations affect response to DSB, we expressed SPOP-wt and SPOP-F133V in benign prostate epithelial cells (RWPE) and prostate cancer cells (22Rv1), and examined the induction, recognition, and resolution of CPT-induced DSBs. We found that DSB formation (measured by γH2AX foci and protein levels) was not affected by modulating SPOP function with siRNA, or expression of wildtype or mutant SPOP (Figure 3C, Figure 3—figure supplement 1C,D). Furthermore, there were no observed differences in early DNA damage signaling events, such as phosphorylation of ATM, ATR, Chk1, and Chk2 (Figure 3—figure supplement 1E–H), indicating that SPOP did not affect initial induction and recognition of DSBs or initial steps in DDR signaling. Consistent with this, SPOP showed only limited co-localization with early markers of DSB (γH2AX, phospho-ATM) in irradiated prostate cells (Figure 3—figure supplement 1I).

Figure 3 with 3 supplements see all

Download asset Open asset

We next examined specific markers (53BP1, RAD51) of the two major DSB repair pathways, HDR and NHEJ. RAD51 is a component of the HDR pathway and a marker for engagement of the HDR machinery (Baumann et al., 1996). 53BP1 is a positive regulator of NHEJ that blocks 5′-DNA-end resection and therefore functions at the intersection of HDR and NHEJ; if 53BP1 is not cleared from sites of DSB by HDR components, it promotes error prone NHEJ (Panier and Boulton, 2014). Strikingly, SPOP-F133V-expressing prostate cells showed delayed clearance of 53BP1 from sites of DSB (Figure 3D,F, Figure 3—figure supplement 3A); similar effects were seen with another SPOP mutation (F102C) commonly observed in prostate cancer (Figure 3—figure supplement 3I,J). Furthermore, SPOP-wt increased RAD51 foci formation compared to controls, while SPOP-F133V-expressing cells showed a dramatic decrease in RAD51 foci formation (Figure 3E,F, Figure 3—figure supplement 3B), consistent with impairment of HDR. Induction of SPOP-F133V in primary MPCs similarly decreased Rad51 foci after IR (Figure 3G,H). Knockdown of SPOP also resulted in a decrease of RAD51 foci, suggesting a selective loss of function of SPOP-F133V in HDR (Figure 3I). We also observed decreased clearance of 53BP1 foci and decreased RAD51 foci formation in SPOP-F133V-expressing cells after gamma irradiation, indicating that this effect is not specific to one mechanism of DSB induction (Figure 3—figure supplement 3C–H). The observed changes in DSB repair were not accompanied by changes in the cell cycle distribution of cells expressing SPOP-wt or F133V under these conditions (Figure 3—figure supplement 3K).

We next investigated the role of SPOP in DSB repair using the well established DR-GFP and Pem1-Ad2-EGFP reporter assays as functional readouts for HDR and NHEJ, respectively (Figure 4A,D) (Pierce et al., 1999; Seluanov et al., 2004). In the DR-GFP assay, knockdown of SPOP by siRNA decreased HDR competence in human epithelial cells to a similar level of BRCA1 knockdown (Figure 4B). Conversely, ectopically expressed SPOP-wt increased the HDR competence in these cells, with partial loss of this function by mutant SPOP (Figure 4C). In contrast, the Pem1-Ad2-EGFP NHEJ reporter assay indicated an increase of NHEJ activity in SPOP-F133V expressing epithelial cells, while both SPOP siRNA and BRCA1 siRNA increased NHEJ (Figure 4E,F). Taken together, these results suggest that SPOP promotes HDR, while somatic mutation in SPOP, as observed in prostate cancer with increased genomic rearrangements, impairs HDR and promotes error-prone NHEJ.

Figure 4

Download asset Open asset

Human cancers with underlying defects in HDR (such as BRCA1 inactivated breast and ovarian cancers) (Bryant et al., 2005; Farmer et al., 2005; Audeh et al., 2010; Tutt et al., 2010) show sensitivity to poly (ADP-ribose) polymerase 1 (PARP) inhibition. To test if SPOP inactivation conferred sensitivity to PARP inhibition after DSB induction, we utilized siRNA targeting SPOP in human prostate cancer cell lines (PC-3, LnCap, 22Rv1), followed by irradiation (5GY) and incubation with the PARP inhibitors olaparib or veliparib. Reduction of SPOP expression increased the sensitivity of these prostate cancer cells to both PARP inhibitors (Figure 5A–C, Figure 5—figure supplement 1B,C). To test if SPOP mutation also sensitizes to PARP inhibition, we treated MPCs (control vs tamoxifen-induced SPOP-F133V) with olaparib followed by IR—expression of SPOP-F133V increased sensitivity to olaparib similar to loss of SPOP in human prostate cancer cell lines (Figure 5D). This was further confirmed in 22Rv1 cells ectopically expressing SPOP-F133V, which also showed an increased sensitivity to olaparib in viability assays, while cells ectopically expressing SPOP-wt were relatively resistant (Figure 5—figure supplement 1A). We further confirmed these results in HEK293 cells stably overexpressing the two common SPOP mutants (Y87N, F133V) in clonogenic survival assays (Figure 5E,F).

Figure 5 with 1 supplement see all

Download asset Open asset

To determine if the altered sensitivity to PARP inhibitors was associated with increased DNA damage, consistent with impaired double-strand break repair, we performed single-cell gel electrophoresis (comet assay) in prostate cells treated with olaparib. The comet assay revealed an increase of genomic instability in SPOP-F133V RWPE cells after PARP inhibition, similar to SPOP (and BRCA1) knockdown with siRNA (Figure 5G). Similarly, primary MPCs expressing SPOP-F133V showed increased damage after olaparib treatment (Figure 5H). Taken together, these data argue that SPOP mutation confers sensitivity to PARP inhibition due to impaired error-free HDR DSB repair and an increase in error-prone NHEJ.

In summary, here we report that SPOP, the substrate recognition component of an E3 ubiquitin ligase, is a regulator of the HDR-based DSB repair machinery. Using functional genetic approaches, we find that prostate-specific SPOP mutants deregulate DSB repair by promoting the error-prone NHEJ pathway (Figure 6). Importantly, after DSB induction, this loss of function leads to an increased sensitivity of mutant SPOP prostate cancer cells to PARP inhibition. These observations provide the first mechanism for the increased genomic instability of SPOP mutant prostate cancer, but also suggest that similar to other cancers with impaired HDR, this distinct class of cancer might benefit from treatment with clinically established DNA damaging therapeutics. This study therefore provides a rationale for hypothesis-based biomarker-driven clinical trials using PARP inhibitors or other DNA damaging agents in patients with prostate cancer.

Figure 6

Download asset Open asset

Genomic rearrangements represent critical events deregulating prostate cancer genomes and driving tumorigenesis, although among individual cancer samples, there is marked variability in number and character of structural rearrangements. Here, we identified a genomically unstable subclass of primary prostate cancer characterized by dramatically increased intrachromosomal rearrangements. This subset of clinically localized, treatment-naive prostate cancers display a degree of genomic instability previously thought only to occur in late stage, metastatic tumors. Importantly, increased rearrangements likely result in higher total SCNA burden, which is associated with more aggressive clinical behavior (Hieronymus et al., 2014; Lalonde et al., 2014).

Increased rearrangements were associated with mutations in SPOP, encoding the substrate-recognition component of an E3 ubiquitin ligase complex. SPOP mutations are the most common point mutations in prostate cancer, but their role in promoting prostate cancer pathogenesis remains unclear. SPOP mutations occur early in the history of prostate cancer, based on clonality analysis reported here and presence in the prostate cancer precursor high grade prostatic intraepithelial neoplasia (HG-PIN) (Barbieri et al., 2012), potentially consistent with a ‘gatekeeper’ role in genome maintenance.

Consistent with increased intrachromosomal rearrangements in SPOP mutant cancers, in vivo data nominated a functional role for SPOP in DSB repair, similar to BRCA1. Interestingly, SPOP loss of function induced a developmental phenotype of neuronal degeneration and apoptosis; similar effects have been reported with other genes modulating DNA repair, including BRCA1 (Pulvers and Huttner, 2009).

SPOP encodes the substrate recognition component of an E3 ubiquitin ligase, and here we identified a role for SPOP in regulating the HDR-based DSB repair machinery. Notably, many established components of the DNA damage response are components of enzymes regulating ubiquitylation (Ceol et al., 2011). A number of substrates have been reported as deregulated by prostate cancer-derived SPOP mutations, but the relevance of these in vitro findings to human prostate cancers is still unclear (Geng et al., 2013, 2014; An et al., 2014; Theurillat et al., 2014; Zhang et al., 2014b). In contrast, we focused on the phenotypes observed in human prostate cancers harboring SPOP mutations. Using functional genetic approaches, we find that prostate-specific SPOP mutants deregulate DSB repair by promoting the error-prone NHEJ pathway (Figure 4F).

The clinical importance of our findings is timely as potent PARP inhibitors, inducing synthetic lethality in cancers with alterations in DSB repair, are being evaluated and utilized in human cancers (Fong et al., 2009; Tutt et al., 2010; Schiewer and Knudsen, 2014). Here, we define a novel biomarker for increased genomic instability in clinically localized prostate cancer, provide the first mechanism by which SPOP mutations induce these alterations, and also suggest that similar to other cancers with impaired HDR, this distinct class of cancer may benefit from treatment with clinically established DNA damaging therapeutics, providing a rationale for genotype-based clinical trials.

1. 1. Prostate Cancer Genome Sequencing Project

   (2012) Prostate Cancer Genome Sequencing Project

   Publicly available at the NCBI (Accession no: phs000447.v1.p1).

   http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000447.v1.p1

1. 1. An J
   2. Wang C
   3. Deng Y
   4. Yu L
   5. Huang H

   (2014) Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants

   Cell Reports 6:657–669.

   https://doi.org/10.1016/j.celrep.2014.01.013

   • Google Scholar
2. 1. Audeh MW
   2. Carmichael J
   3. Penson RT
   4. Friedlander M
   5. Powell B
   6. Bell-McGuinn KM
   7. Scott C
   8. Weitzel JN
   9. Oaknin A
   10. Loman N
   11. Lu K
   12. Schmutzler RK
   13. Matulonis U
   14. Wickens M
   15. Tutt A

   (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

   Lancet 376:245–251.

   https://doi.org/10.1016/S0140-6736(10)60893-8

   • Google Scholar
3. 1. Baca SC
   2. Prandi D
   3. Lawrence MS
   4. Mosquera JM
   5. Romanel A
   6. Drier Y
   7. Park K
   8. Kitabayashi N
   9. MacDonald TY
   10. Ghandi M
   11. Van Allen E
   12. Kryukov GV
   13. Sboner A
   14. Theurillat JP
   15. Soong TD
   16. Nickerson E
   17. Auclair D
   18. Tewari A
   19. Beltran H
   20. Onofrio RC
   21. Boysen G
   22. Guiducci C
   23. Barbieri CE
   24. Cibulskis K
   25. Sivachenko A
   26. Carter SL
   27. Saksena G
   28. Voet D
   29. Ramos AH
   30. Winckler W
   31. Cipicchio M
   32. Ardlie K
   33. Kantoff PW
   34. Berger MF
   35. Gabriel SB
   36. Golub TR
   37. Meyerson M
   38. Lander ES
   39. Elemento O
   40. Getz G
   41. Demichelis F
   42. Rubin MA
   43. Garraway LA

   (2013) Punctuated evolution of prostate cancer genomes

   Cell 153:666–677.

   https://doi.org/10.1016/j.cell.2013.03.021

   • Google Scholar
4. 1. Barbieri CE
   2. Baca SC
   3. Lawrence MS
   4. Demichelis F
   5. Blattner M
   6. Theurillat JP
   7. White TA
   8. Stojanov P
   9. Van Allen E
   10. Stransky N
   11. Nickerson E
   12. Chae SS
   13. Boysen G
   14. Auclair D
   15. Onofrio RC
   16. Park K
   17. Kitabayashi N
   18. MacDonald TY
   19. Sheikh K
   20. Vuong T
   21. Guiducci C
   22. Cibulskis K
   23. Sivachenko A
   24. Carter SL
   25. Saksena G
   26. Voet D
   27. Hussain WM
   28. Ramos AH
   29. Winckler W
   30. Redman MC
   31. Ardlie K
   32. Tewari AK
   33. Mosquera JM
   34. Rupp N
   35. Wild PJ
   36. Moch H
   37. Morrissey C
   38. Nelson PS
   39. Kantoff PW
   40. Gabriel SB
   41. Golub TR
   42. Meyerson M
   43. Lander ES
   44. Getz G
   45. Rubin MA
   46. Garraway LA

   (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

   Nature Genetics 44:685–689.

   https://doi.org/10.1038/ng.2279

   • Google Scholar
5. 1. Baumann P
   2. Benson FE
   3. West SC

   (1996) Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro

   Cell 87:757–766.

   https://doi.org/10.1016/S0092-8674(00)81394-X

   • Google Scholar
6. 1. Beroukhim R
   2. Mermel CH
   3. Porter D
   4. Wei G
   5. Raychaudhuri S
   6. Donovan J
   7. Barretina J
   8. Boehm JS
   9. Dobson J
   10. Urashima M
   11. Mc Henry KT
   12. Pinchback RM
   13. Ligon AH
   14. Cho YJ
   15. Haery L
   16. Greulich H
   17. Reich M
   18. Winckler W
   19. Lawrence MS
   20. Weir BA
   21. Tanaka KE
   22. Chiang DY
   23. Bass AJ
   24. Loo A
   25. Hoffman C
   26. Prensner J
   27. Liefeld T
   28. Gao Q
   29. Yecies D
   30. Signoretti S
   31. Maher E
   32. Kaye FJ
   33. Sasaki H
   34. Tepper JE
   35. Fletcher JA
   36. Tabernero J
   37. Baselga J
   38. Tsao MS
   39. Demichelis F
   40. Rubin MA
   41. Janne PA
   42. Daly MJ
   43. Nucera C
   44. Levine RL
   45. Ebert BL
   46. Gabriel S
   47. Rustgi AK
   48. Antonescu CR
   49. Ladanyi M
   50. Letai A
   51. Garraway LA
   52. Loda M
   53. Beer DG
   54. True LD
   55. Okamoto A
   56. Pomeroy SL
   57. Singer S
   58. Golub TR
   59. Lander ES
   60. Getz G
   61. Sellers WR
   62. Meyerson M

   (2010) The landscape of somatic copy-number alteration across human cancers

   Nature 463:899–905.

   https://doi.org/10.1038/nature08822

   • Google Scholar
7. 1. Blattner M
   2. Lee DJ
   3. O'Reilly C
   4. Park K
   5. MacDonald TY
   6. Khani F
   7. Turner KR
   8. Chiu YL
   9. Wild PJ
   10. Dolgalev I
   11. Heguy A
   12. Sboner A
   13. Ramazangolu S
   14. Hieronymus H
   15. Sawyers C
   16. Tewari AK
   17. Moch H
   18. Yoon GS
   19. Known YC
   20. Andrén O
   21. Fall K
   22. Demichelis F
   23. Mosquera JM
   24. Robinson BD
   25. Barbieri CE
   26. Rubin MA

   (2014) SPOP mutations in prostate cancer across demographically diverse patient cohorts

   Neoplasia 16:14–20.

   https://doi.org/10.1593/neo.131704

   • Google Scholar
8. 1. Bryant HE
   2. Schultz N
   3. Thomas HD
   4. Parker KM
   5. Flower D
   6. Lopez E
   7. Kyle S
   8. Meuth M
   9. Curtin NJ
   10. Helleday T

   (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

   Nature 434:913–917.

   https://doi.org/10.1038/nature03443

   • Google Scholar
9. 1. Ceol CJ
   2. Houvras Y
   3. Jane-Valbuena J
   4. Bilodeau S
   5. Orlando DA
   6. Battisti V
   7. Fritsch L
   8. Lin WM
   9. Hollmann TJ
   10. Ferré F
   11. Bourque C
   12. Burke CJ
   13. Turner L
   14. Uong A
   15. Johnson LA
   16. Beroukhim R
   17. Mermel CH
   18. Loda M
   19. Ait-Si-Ali S
   20. Garraway LA
   21. Young RA
   22. Zon LI

   (2011) The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset

   Nature 471:513–517.

   https://doi.org/10.1038/nature09806

   • Google Scholar
10. 1. Chen Y
    2. Chi P
    3. Rockowitz S
    4. Iaquinta PJ
    5. Shamu T
    6. Shukla S
    7. Gao D
    8. Sirota I
    9. Carver BS
    10. Wongvipat J
    11. Scher HI
    12. Zheng D
    13. Sawyers CL

    (2013) ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss

    Nature Medicine 19:1023–1029.

    https://doi.org/10.1038/nm.3216

    • Google Scholar
11. 1. Cher ML
    2. Bova GS
    3. Moore DH
    4. Small EJ
    5. Carroll PR
    6. Pin SS
    7. Epstein JI
    8. Isaacs WB
    9. Jensen RH

    (1996)

    Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping

    Cancer Research 56:3091–3102.

    • Google Scholar
12. 1. Consortium TCGA

    (2015)

    The molecular taxonomy of primary prostate cancer

    Cell, Forthcoming.

    • Google Scholar
13. 1. Demichelis F
    2. Setlur SR
    3. Beroukhim R
    4. Perner S
    5. Korbel JO
    6. Lafargue CJ
    7. Pflueger D
    8. Pina C
    9. Hofer MD
    10. Sboner A
    11. Svensson MA
    12. Rickman DS
    13. Urban A
    14. Snyder M
    15. Meyerson M
    16. Lee C
    17. Gerstein MB
    18. Kuefer R
    19. Rubin MA

    (2009) Distinct genomic aberrations associated with ERG rearranged prostate cancer

    Genes, Chromosomes & Cancer 48:366–380.

    https://doi.org/10.1002/gcc.20647

    • Google Scholar
14. 1. Farmer H
    2. McCabe N
    3. Lord CJ
    4. Tutt AN
    5. Johnson DA
    6. Richardson TB
    7. Santarosa M
    8. Dillon KJ
    9. Hickson I
    10. Knights C
    11. Martin NM
    12. Jackson SP
    13. Smith GC
    14. Ashworth A

    (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

    Nature 434:917–921.

    https://doi.org/10.1038/nature03445

    • Google Scholar
15. 1. Fong PC
    2. Boss DS
    3. Yap TA
    4. Tutt A
    5. Wu P
    6. Mergui-Roelvink M
    7. Mortimer P
    8. Swaisland H
    9. Lau A
    10. O'Connor MJ
    11. Ashworth A
    12. Carmichael J
    13. Kaye SB
    14. Schellens JH
    15. de Bono JS

    (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

    The New England Journal of Medicine 361:123–134.

    https://doi.org/10.1056/NEJMoa0900212

    • Google Scholar
16. 1. Garraway LA
    2. Lander ES

    (2013) Lessons from the cancer genome

    Cell 153:17–37.

    https://doi.org/10.1016/j.cell.2013.03.002

    • Google Scholar
17. 1. Geng C
    2. He B
    3. Xu L
    4. Barbieri CE
    5. Eedunuri VK
    6. Chew SA
    7. Zimmermann M
    8. Bond R
    9. Shou J
    10. Li C
    11. Blattner M
    12. Lonard DM
    13. Demichelis F
    14. Coarfa C
    15. Rubin MA
    16. Zhou P
    17. O'Malley BW
    18. Mitsiades N

    (2013) Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover

    Proceedings of the National Academy of Sciences of USA 110:6997–7002.

    https://doi.org/10.1073/pnas.1304502110

    • Google Scholar
18. 1. Geng C
    2. Rajapakshe K
    3. Shah SS
    4. Shou J
    5. Eedunuri VK
    6. Foley C
    7. Fiskus W
    8. Rajendran M
    9. Chew SA
    10. Zimmermann M
    11. Bond R
    12. He B
    13. Coarfa C
    14. Mitsiades N

    (2014) Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer

    Cancer Research 74:5631–5643.

    https://doi.org/10.1158/0008-5472.CAN-14-0476

    • Google Scholar
19. 1. Hanahan D
    2. Weinberg RA

    (2011) Hallmarks of cancer: the next generation

    Cell 144:646–674.

    https://doi.org/10.1016/j.cell.2011.02.013

    • Google Scholar
20. 1. Hieronymus H
    2. Schultz N
    3. Gopalan A
    4. Carver BS
    5. Chang MT
    6. Xiao Y
    7. Heguy A
    8. Huberman K
    9. Bernstein M
    10. Assel M
    11. Murali R
    12. Vickers A
    13. Scardino PT
    14. Sander C
    15. Reuter V
    16. Taylor BS
    17. Sawyers CL

    (2014) Copy number alteration burden predicts prostate cancer relapse

    Proceedings of the National Academy of Sciences of USA 111:11139–11144.

    https://doi.org/10.1073/pnas.1411446111

    • Google Scholar
21. 1. Karthaus WR
    2. Iaquinta PJ
    3. Drost J
    4. Gracanin A
    5. van Boxtel R
    6. Wongvipat J
    7. Dowling CM
    8. Gao D
    9. Begthel H
    10. Sachs N
    11. Vries RG
    12. Cuppen E
    13. Chen Y
    14. Sawyers CL
    15. Clevers HC

    (2014) Identification of multipotent luminal progenitor cells in human prostate organoid cultures

    Cell 159:163–175.

    https://doi.org/10.1016/j.cell.2014.08.017

    • Google Scholar
22. 1. Lalonde E
    2. Ishkanian AS
    3. Sykes J
    4. Fraser M
    5. Ross-Adams H
    6. Erho N
    7. Dunning MJ
    8. Halim S
    9. Lamb AD
    10. Moon NC
    11. Zafarana G
    12. Warren AY
    13. Meng X
    14. Thoms J
    15. Grzadkowski MR
    16. Berlin A
    17. Have CL
    18. Ramnarine VR
    19. Yao CQ
    20. Malloff CA
    21. Lam LL
    22. Xie H
    23. Harding NJ
    24. Mak DY
    25. Chu KC
    26. Chong LC
    27. Sendorek DH
    28. P'ng C
    29. Collins CC
    30. Squire JA
    31. Jurisica I
    32. Cooper C
    33. Eeles R
    34. Pintilie M
    35. Dal Pra A
    36. Davicioni E
    37. Lam WL
    38. Milosevic M
    39. Neal DE
    40. van der Kwast T
    41. Boutros PC
    42. Bristow RG

    (2014) Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study

    The Lancet Oncology 15:1521–1532.

    https://doi.org/10.1016/S1470-2045(14)71021-6

    • Google Scholar
23. 1. Liu W
    2. Chang B
    3. Sauvageot J
    4. Dimitrov L
    5. Gielzak M
    6. Li T
    7. Yan G
    8. Sun J
    9. Sun J
    10. Adams TS
    11. Turner AR
    12. Kim JW
    13. Meyers DA
    14. Zheng SL
    15. Isaacs WB
    16. Xu J

    (2006) Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array

    Genes, Chromosomes & Cancer 45:1018–1032.

    https://doi.org/10.1002/gcc.20369

    • Google Scholar
24. 1. Lukacs RU
    2. Goldstein AS
    3. Lawson DA
    4. Cheng D
    5. Witte ON

    (2010) Isolation, cultivation and characterization of adult murine prostate stem cells

    Nature Protocols 5:702–713.

    https://doi.org/10.1038/nprot.2010.11

    • Google Scholar
25. 1. Panier S
    2. Boulton SJ

    (2014) Double-strand break repair: 53BP1 comes into focus

    Nature Reviews Molecular Cell Biology 15:7–18.

    https://doi.org/10.1038/nrm3719

    • Google Scholar
26. 1. Pierce AJ
    2. Johnson RD
    3. Thompson LH
    4. Jasin M

    (1999) XRCC3 promotes homology-directed repair of DNA damage in mammalian cells

    Genes & Development 13:2633–2638.

    https://doi.org/10.1101/gad.13.20.2633

    • Google Scholar
27. 1. Prandi D
    2. Baca SC
    3. Romanel A
    4. Barbieri CE
    5. Mosquera JM
    6. Fontugne J
    7. Beltran H
    8. Sboner A
    9. Garraway LA
    10. Rubin MA
    11. Demichelis F

    (2014) Unraveling the clonal hierarchy of somatic genomic aberrations

    Genome Biology 15:439.

    https://doi.org/10.1186/s13059-014-0439-6

    • Google Scholar
28. 1. Pulvers JN
    2. Huttner WB

    (2009) Brca1 is required for embryonic development of the mouse cerebral cortex to normal size by preventing apoptosis of early neural progenitors

    Development 136:1859–1868.

    https://doi.org/10.1242/dev.033498

    • Google Scholar
29. 1. Schiewer MJ
    2. Knudsen KE

    (2014) Transcriptional roles of PARP1 in cancer

    Molecular Cancer Research 12:1069–1080.

    https://doi.org/10.1158/1541-7786.MCR-13-0672

    • Google Scholar
30. 1. Seluanov A
    2. Mittelman D
    3. Pereira-Smith OM
    4. Wilson JH
    5. Gorbunova V

    (2004) DNA end joining becomes less efficient and more error-prone during cellular senescence

    Proceedings of the National Academy of Sciences of USA 101:7624–7629.

    https://doi.org/10.1073/pnas.0400726101

    • Google Scholar
31. 1. Theurillat JP
    2. Udeshi ND
    3. Errington WJ
    4. Svinkina T
    5. Baca SC
    6. Pop M
    7. Wild PJ
    8. Blattner M
    9. Groner AC
    10. Rubin MA
    11. Moch H
    12. Privé GG
    13. Carr SA
    14. Garraway LA

    (2014) Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer

    Science 346:85–89.

    https://doi.org/10.1126/science.1250255

    • Google Scholar
32. 1. Tomlins SA
    2. Rhodes DR
    3. Perner S
    4. Dhanasekaran SM
    5. Mehra R
    6. Sun XW
    7. Varambally S
    8. Cao X
    9. Tchinda J
    10. Kuefer R
    11. Lee C
    12. Montie JE
    13. Shah RB
    14. Pienta KJ
    15. Rubin MA
    16. Chinnaiyan AM

    (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer

    Science 310:644–648.

    https://doi.org/10.1126/science.1117679

    • Google Scholar
33. 1. Tutt A
    2. Robson M
    3. Garber JE
    4. Domchek SM
    5. Audeh MW
    6. Weitzel JN
    7. Friedlander M
    8. Arun B
    9. Loman N
    10. Schmutzler RK
    11. Wardley A
    12. Mitchell G
    13. Earl H
    14. Wickens M
    15. Carmichael J

    (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

    Lancet 376:235–244.

    https://doi.org/10.1016/S0140-6736(10)60892-6

    • Google Scholar
34. 1. Visakorpi T
    2. Kallioniemi AH
    3. Syvänen AC
    4. Hyytinen ER
    5. Karhu R
    6. Tammela T
    7. Isola JJ
    8. Kallioniemi OP

    (1995)

    Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization

    Cancer Research 55:342–347.

    • Google Scholar
35. 1. Zhang D
    2. Wang H
    3. Sun M
    4. Yang J
    5. Zhang W
    6. Han S
    7. Xu B

    (2014a) Speckle-type POZ protein, SPOP, is involved in the DNA damage response

    Carcinogenesis 35:1691–1697.

    https://doi.org/10.1093/carcin/bgu022

    • Google Scholar
36. 1. Zhang P
    2. Gao K
    3. Tang Y
    4. Jin X
    5. An J
    6. Yu H
    7. Wang H
    8. Zhang Y
    9. Wang D
    10. Huang H
    11. Yu L
    12. Wang C

    (2014b) Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants

    Human Mutation 35:1142–1151.

    https://doi.org/10.1002/humu.22614

    • Google Scholar
37. 1. Zhao H
    2. Kim Y
    3. Wang P
    4. Lapointe J
    5. Tibshirani R
    6. Pollack JR
    7. Brooks JD

    (2005) Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines

    The Prostate 63:187–197.

    https://doi.org/10.1002/pros.20158

    • Google Scholar

Author details

1. Gunther Boysen

   1. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
   2. Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom
   3. The Royal Marsden, London, United Kingdom

   Contribution

   GB, Final approval of the version to be published, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

   Contributed equally with

   Christopher E Barbieri

   Competing interests

   No competing interests declared.

2. Christopher E Barbieri

   1. Department of Urology, Weill Cornell Medical College, New York, United States
   2. Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, United States

   Contribution

   CEB, Final approval of the version to be published, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

   Contributed equally with

   Gunther Boysen

   For correspondence

   chb9074@med.cornell.edu

   Competing interests

   CEB: A patent (US Patent Application No: 2013/0331,279) has been issued to Weill Medical College of Cornell University on SPOP mutations in prostate cancer; is listed as co-inventor.

3. Davide Prandi

   Centre for Integrative Biology, University of Trento, Trento, Italy

   Contribution

   DP, Final approval of the version to be published, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

   Competing interests

   No competing interests declared.

4. Mirjam Blattner

   Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States

   Contribution

   MB, Final approval of the version to be published, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

   Competing interests

   No competing interests declared.

5. Sung-Suk Chae

   Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States

   Contribution

   S-SC, Final approval of the version to be published, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

   Competing interests

   No competing interests declared.

6. Arun Dahija

   Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States

   Contribution

   FD, Final approval of the version to be published, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

   Competing interests

   No competing interests declared.

7. Srilakshmi Nataraj

   Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States

   Contribution

   AD, Final approval of the version to be published, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

   Competing interests

   No competing interests declared.

8. Dennis Huang

   Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States

   Contribution

   SN, Final approval of the version to be published, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

   Competing interests

   No competing interests declared.

9. Clarisse Marotz

   Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States

   Contribution

   DH, Final approval of the version to be published, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

   Competing interests

   No competing interests declared.

10. Limei Xu

    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States

    Contribution

    CM, Final approval of the version to be published, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

    Competing interests

    No competing interests declared.

11. Julie Huang

    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States

    Contribution

    LX, Final approval of the version to be published, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

    Competing interests

    No competing interests declared.

12. Paola Lecca

    Centre for Integrative Biology, University of Trento, Trento, Italy

    Contribution

    JH, Final approval of the version to be published, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

    Competing interests

    No competing interests declared.

13. Sagar Chhangawala

    1. Department of Surgery, Weill Cornell Medical College, New York, United States
    2. HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States

    Contribution

    PL, Final approval of the version to be published, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

    Competing interests

    No competing interests declared.

14. Deli Liu

    1. Department of Urology, Weill Cornell Medical College, New York, United States
    2. HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States

    Contribution

    SC, Final approval of the version to be published, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

    Competing interests

    No competing interests declared.

15. Pengbo Zhou

    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States

    Contribution

    DL, Final approval of the version to be published, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

    Competing interests

    No competing interests declared.

16. Andrea Sboner

    1. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    2. HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States
    3. Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, United States

    Contribution

    PZ, Final approval of the version to be published, Conception and design, Analysis and interpretation of data, Drafting or revising the article

    Competing interests

    No competing interests declared.

17. Johann S de Bono

    1. Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom
    2. The Royal Marsden, London, United Kingdom

    Contribution

    AS, Final approval of the version to be published, Conception and design, Analysis and interpretation of data, Drafting or revising the article

    Competing interests

    No competing interests declared.

18. Francesca Demichelis

    1. Centre for Integrative Biology, University of Trento, Trento, Italy
    2. HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States
    3. Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, United States

    Contribution

    JSB, Final approval of the version to be published, Conception and design, Analysis and interpretation of data, Drafting or revising the article

    Contributed equally with

    Yariv Houvras and Mark A Rubin

    Competing interests

    No competing interests declared.

19. Yariv Houvras

    1. Department of Surgery, Weill Cornell Medical College, New York, United States
    2. Department of Medicine, Weill Cornell Medical College, New York, United States

    Contribution

    YH, Final approval of the version to be published, Conception and design, Analysis and interpretation of data, Drafting or revising the article

    Contributed equally with

    Francesca Demichelis and Mark A Rubin

    Competing interests

    No competing interests declared.

20. Mark A Rubin

    1. Department of Urology, Weill Cornell Medical College, New York, United States
    2. Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, United States
    3. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
    4. Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, United States

    Contribution

    MAR, Final approval of the version to be published, Conception and design, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents

    Contributed equally with

    Francesca Demichelis and Yariv Houvras

    For correspondence

    rubinma@med.cornell.edu

    Competing interests

    MAR: A patent (US Patent Application No: 2013/0331,279) has been issued to Weill Medical College of Cornell University on SPOP mutations in prostate cancer; is listed as co-inventor.

• 7,215

  views

• 1,473

  downloads

• 144

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.